Levetiracetam and Sodium Valproate Show Similar Results for Epilepsy

Source: Indian journal of pediatrics

Summary

A study was conducted to compare two medications, sodium valproate (VPA) and levetiracetam (LEV), for treating children aged 2 to 18 who were newly diagnosed with epilepsy. The researchers wanted to see which medication was more effective at controlling seizures when used as the first treatment. A total of 116 children participated, with 58 receiving VPA and 58 receiving LEV.

The key findings showed that both medications had similar success rates in controlling seizures over three months. About 58.6% of the children on LEV and 65.5% on VPA achieved seizure control, which was not a significant difference. Additionally, both groups had similar rates of patients who experienced a 50% reduction in seizures. However, children taking LEV gained less weight compared to those on VPA, which could be an important consideration for parents.

This study is important because it suggests that levetiracetam can be a safe and effective first treatment option for children with new-onset epilepsy, similar to sodium valproate. However, it is worth noting that the study had limitations, such as a small number of participants and a short follow-up period. Parents and caregivers should discuss these findings with their healthcare providers to make informed decisions about treatment options.

Original source